Delandistrogene moxeparvovec, a gene therapy approved for the treatment of Duchenne muscular dystrophy (DMD), was found ...

Abdelghani M, et al . Experimental myositis: an optimised version of C-protein-induced myositis. RMD Open 2025;11:e004558. doi: 10.1136/rmdopen-2024–0 04 558 In this article, the abstract has been ...

Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Your muscles get tired due to repeated use, lactic acid buildup, dehydration, poor nutrition, underlying health conditions, ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimm ...

Rheumatologists and cardiologists have long co-managed patients out of necessity and without much formal collaboration or ...

Corient Private Wealth LLC grew its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 14.7% in the 4th quarter, ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

Farther Finance Advisors LLC grew its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 38.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 76 shares ...

Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...